Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis.

CONCLUSION: Twice-daily GSP301 treatment was efficacious and well tolerated, providing statistically significant and clinically meaningful improvements in rTNSS (primary endpoint) versus placebo and both monotherapies. PMID: 31734334 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31734334?dopt=Abstract

Source: Annals of Allergy, Asthma and Immunology - November 13, 2019 Category: Allergy & Immunology Authors: Andrews CP, Mohar D, Salhi Y, Tantry SK Tags: Ann Allergy Asthma Immunol Source Type: research